Core Viewpoint - The controversy surrounding the cosmetic brand "Kefumei" and its alleged false advertising of a collagen product has escalated, leading to significant public attention and legal implications for the involved parties [1][3]. Group 1: Company Responses - "Giant Bio" issued a statement acknowledging the apology from the testing agency used by "Dr. Big Mouth" and emphasized that the agency did not authorize the testing report [4]. - "Giant Bio" reiterated that their product contains real recombinant collagen protein and denied any allegations of false advertising or misleading consumers [5]. - "Huaxi Bio" publicly supported "Dr. Big Mouth," stating that the company is an important member of its ecosystem and has invested in related ventures [4]. Group 2: Influencer Background - "Dr. Big Mouth," whose real name is Hao Yu, is a well-known beauty influencer with over 2.8 million followers across various platforms and holds a PhD in chemistry from the University of Hong Kong [3]. - The influencer's allegations against "Giant Bio" regarding the authenticity of their collagen product gained significant traction, even trending on social media [3]. Group 3: Legal and Regulatory Implications - "Giant Bio" announced intentions to pursue legal action against those spreading false information, highlighting the seriousness of the allegations and the potential impact on their brand [4]. - The testing agency involved has demanded that "Dr. Big Mouth" cease using and sharing the disputed test report to prevent further public misinformation [4].

Core Viewpoint - The controversy surrounding the collagen product "Kefumei" and its alleged false claims has led to significant media attention and a public dispute between two major players in the beauty and medical aesthetics industry, Juzhibio and Huaxi Biological. Group 1: Allegations and Responses - The beauty blogger "Dr. Big Mouth" raised concerns about the collagen content in "Kefumei" products, claiming it was only 0.02%, below the regulatory threshold of 0.1% [5] - Juzhibio, the parent company of "Kefumei," denied these allegations, asserting that their internal tests showed collagen content exceeding 0.1%, with third-party tests indicating levels between 0.2% and 0.22% [8] - The blogger's videos related to Juzhibio were removed from social media platforms, which he attributed to malicious reporting rather than voluntary deletion [1] Group 2: Industry Dynamics - The dispute is seen as a competitive clash between Juzhibio and Huaxi Biological, with the latter supporting the blogger's claims and hinting at a potential "business war" [8] - Juzhibio's market capitalization is reported to be over twice that of Huaxi Biological, despite similar performance levels, indicating a market preference for Juzhibio's collagen products [8] - Huaxi Biological had previously attempted to enter the collagen market through acquisitions, indicating a strategic interest in this segment [9] Group 3: Market Impact - Following the public dispute, both Juzhibio and Huaxi Biological experienced stock price declines, with Juzhibio opening at 59.8 HKD per share and Huaxi Biological at 54.34 CNY per share [11]

Core Viewpoint - The article discusses the ongoing competition between two major players in the medical beauty industry, Huaxi Biological and Juzhi Biological, highlighting the market dynamics and the impact of recent controversies on their valuations and reputations [4][12][44]. Group 1: Market Dynamics - Huaxi Biological publicly criticized the notion that hyaluronic acid is outdated, directly targeting nine brokerage firms for their lack of rigor in research reports, which favored Juzhi Biological [4][12]. - Juzhi Biological's market capitalization has decreased significantly, dropping to approximately HKD 65 billion, a nearly one-third reduction from its peak on May 20 [8][46]. - The medical beauty market is experiencing rapid changes, with Juzhi Biological's revenue surpassing Huaxi Biological's in 2024, and its net profit being nearly twelve times that of Huaxi Biological [12][44]. Group 2: Controversies and Responses - Juzhi Biological faced allegations of product ingredient fraud, specifically regarding its core product, Kefu Mei, which is crucial for its revenue [6][29]. - The company initially responded slowly to the allegations, which led to investor dissatisfaction and a significant drop in stock price [28][29]. - Despite attempts to clarify the situation through third-party testing, Juzhi Biological's responses have been met with skepticism, particularly regarding the validity of their testing methods [26][27]. Group 3: Competitive Landscape - The competition between Huaxi Biological and Juzhi Biological is characterized as a market "replacement," with both companies vying for dominance in the medical beauty sector [13][44]. - Huaxi Biological's management attributes the market shift to capital chasing new trends, particularly the rise of collagen products over hyaluronic acid [44][45]. - The article emphasizes the fragility of the business models in the medical beauty industry, as both companies heavily rely on specific products, making them vulnerable to market changes [47][48].

Core Viewpoint - The botulinum toxin industry in China is experiencing rapid growth, with the market size projected to increase from 1.9 billion yuan in 2017 to 9.9 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 26.6% [1][13]. Industry Overview - Botulinum toxin, originally used for treating muscle spasms, has become a popular choice in medical aesthetics due to its minimal invasiveness and quick recovery time [3][13]. - The application range of botulinum toxin is expanding beyond traditional uses like wrinkle reduction and facial slimming to include treatments for conditions such as migraines and muscle tension disorders [1][13]. Market Dynamics - The medical aesthetics market in China is projected to reach 288 billion yuan by 2024, with a year-on-year increase of 8.03%, indicating a growing consumer demand for beauty enhancement services [11][13]. - The market is characterized by a "six-way split" among leading products, with brands like Botox, Hengli, and Letyb gaining significant market shares [15][17]. Competitive Landscape - The botulinum toxin market is competitive, with established companies like Fosun Pharma, Haohai Biological Technology, and Lanzhou Biological Products Research Institute leading the industry [17][18]. - New entrants are emerging, leveraging innovative technologies and marketing strategies to capture market share [17]. Development Trends 1. **Increasing Industry Penetration** - As living standards rise, the penetration rate of medical aesthetics is expected to increase, particularly in lower-tier cities and rural areas, driven by a younger consumer base [23]. 2. **Enhanced Regulatory Oversight** - The government is intensifying regulations on botulinum toxin production and distribution to ensure safety and quality, which will promote the healthy development of the market [24]. 3. **Rise of Recombinant Botulinum Toxin** - Recombinant botulinum toxin is anticipated to become a future trend due to its lower biological risks, higher purity, and production efficiency, addressing limitations of traditional products [25].

Core Viewpoint - The first Global Aesthetic Technology Conference 2025 was held in Beijing, showcasing innovations in the medical aesthetics industry and promoting technology transfer and cross-industry collaboration [2]. Group 1: Awards Overview - The conference featured the announcement of the 2025 Global Aesthetic Technology Innovation Awards, which included three categories: Technology Innovation Award, Innovation Service Award, and Innovation Transformation Award [2]. Group 2: Technology Innovation Award Winners - Huaxi Biological was recognized for its integration of basic research and industrial transformation, particularly through its brand Runzhi, which focuses on high-quality materials for injection and tissue repair [5]. - Langxi Ziyuan Medical Devices developed a comprehensive technology system for regenerative medicine, enhancing exosome therapy for chronic wound repair with a 3D biomimetic culture system [6]. - Weimai Qingtong Medical Technology launched a new monopolar RF anti-aging system, YOUMAGIC, which has received both NMPA and FDA approvals, breaking international monopolies in high-end RF equipment [8]. - Suzhou Baifu Laser Technology specializes in high-end medical laser equipment, achieving significant technological breakthroughs in various laser types, enhancing treatment precision and safety [10]. - Suzhou Fumailai Medical Technology focuses on innovative design and application of high-end medical optical devices, achieving breakthroughs in energy stability and treatment accuracy [12]. - Guangzhou Yicheng Biological Technology emphasizes the development of innovative materials for injection fillers and sutures, providing reliable domestic raw material sources [13]. Group 3: Innovation Service Award Winners - Beijing Tonghe Litai Bio-Tech specializes in preclinical research for medical devices, having completed over 900 NMPA registration reports, ensuring scientific data and compliance for innovative products [16]. - Beijing Baoli Yongchang Medical Technology (Lihe Kang) has developed a mature methodology for compliance transformation services in the medical aesthetics field, facilitating the rapid market entry of innovative products [17]. - Hainan Susong Biological Technology introduced Swiss SmartBone® on Demand bone regeneration materials, demonstrating effective cross-border medical technology integration [19]. Group 4: Innovation Transformation Award Winners - Yao Guijin led the establishment of an ecosystem for medical aesthetic technology transformation, connecting medical, research, enterprise, and regulatory sectors [21]. - Professor An Yang's team developed solutions for nasal reconstruction, enhancing tissue regeneration and application in aesthetic surgery [22]. - Professor Niu Xufeng innovated a composite material system for skin fillers, addressing common industry challenges and improving product stability [23]. - Professor Zhang Guifeng achieved breakthroughs in medical collagen research, establishing a closed-loop system for industry standards and quality control [24]. Conclusion - The awards highlighted the breadth and depth of innovation in the medical aesthetics sector, showcasing the emerging strength of Chinese companies and experts in the global industry landscape [25].

Core Viewpoint - The first Global Aesthetic Technology Conference 2025 was held in Beijing, showcasing innovations in the medical aesthetics industry and promoting technology transfer and cross-industry collaboration [2] Group 1: Awards Overview - The conference featured the 2025 Global Aesthetic Technology Innovation Awards, which included three categories: Technology Innovation Award, Innovation Service Award, and Innovation Transformation Award, highlighting innovations in materials, equipment, and technology transfer in China's medical aesthetics sector [2] Group 2: Technology Innovation Award Winners - Huaxi Biological was recognized for its integration of basic research and industrial transformation, particularly through its brand Runzhi, which utilizes synthetic biology technology in hyaluronic acid and extracellular matrix [4] - Langxi Ziyuan Medical Devices focused on regenerative medicine and developed a 3D biomimetic culture system that enhances the yield and bioactivity of exosomes for chronic wound repair [5] - Weimai Qingtong Medical Technology created a new monopolar RF anti-aging system, YOUMAGIC, which has received both NMPA and FDA approvals, breaking the international brand monopoly in high-end RF equipment [7] - Suzhou Baifu Laser Technology specializes in high-end medical laser equipment, achieving significant technological breakthroughs in stability and precision, with products that meet international standards [9] - Suzhou Fumai Lei Medical Technology has developed innovative high-end medical optical devices, focusing on energy stability and treatment precision, contributing to the rise of domestic optical medical equipment [11] - Guangzhou Yicheng Biological focuses on regenerative materials and has developed various medical devices with a clear product line and compliance registration paths [12] Group 3: Innovation Service Award Winners - Beijing Tonghe Litai Biotechnology specializes in preclinical research for medical devices, having completed over 900 NMPA registration reports, ensuring scientific data and compliance for innovative medical products [14] - Beijing Baoli Yongchang Medical Technology (Lihokang) has established a mature methodology for compliance transformation services in the medical aesthetics field, facilitating the rapid market entry of innovative products [16] - Hainan Susong Biotechnology has introduced Swiss SmartBone® on Demand bone regeneration materials, demonstrating effective cross-border medical technology integration and personalized medical needs [17] Group 4: Innovation Transformation Award Winners - Yao Guijin led the establishment of an ecosystem for medical aesthetics technology transfer, facilitating collaboration among medical, research, enterprise, and regulatory sectors [19] - Professor An Yang's team developed solutions for nasal reconstruction, achieving significant advancements in tissue regeneration and repair [20] - Professor Niu Xufeng addressed common issues in skin fillers by innovating a polyester microsphere/collagen composite material system, enhancing stability and integration [21] - Professor Zhang Guifeng made breakthroughs in medical collagen research, establishing a closed-loop system for industry standards and quality control [22] Conclusion - The Global Aesthetic Technology Awards highlighted the breadth and depth of innovation in the medical aesthetics sector, showcasing the emerging strength of Chinese companies and experts in the global industry landscape [23]

中国北京建国门外大街 1 号国贸写字楼 2 座 12 -15 层 100004 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 致：华熙生物科技股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》(以下简称"《证券法》")、 《上市公司股东会规则》(以下简称"《股 东会规则》")等法律、法规及规范性文件和《华熙生物科技股份有限公司章程》 (以下简称"《公司章程》")的规定，北京市通商律师事务所(以下简称"通商" 或"本所")接受华熙生物科技股份有限公司(以下简称"公司")委托，指派本所 律师出席了公司于 2025 年 6 月 11 日召开的 2024 年年度股东大会(以下简称"本 次股东大会")，并就本次股东大会的相关事项出具本法律意见书。 本法律意见书仅供公司本次股东大会之目的使用，本所律师同意将本法律意 见书随公司本次股东大会其他信息披露资料一并 ...

| 证券代码：688363 证券简称：华熙生物 公告编号：2025-021 | | | | | | | --- | --- | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | 重要内容提示： | | | | | | | ? 本次会议是否有被否决议案：无 | | | | | | | 一、 会议召开和出席情况 | | | | | | | （一） 股东大会召开的时间：2025 年 06 日 | | 月 11 | | | | | （二） 股东大会召开的地点：浙江省杭州市钱塘区海达北路 号康洲科创园 | | | | 399 | | | B1 座 1 层 | | | | | | | （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | | | | | | | 其持有表决权数量的情况： | | | | | | | 普通股股东人数 | | | | 188 | ...

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management personnel at Huaxi Biological Technology Co., Ltd. The third board of directors has been elected for a term of three years, and key management positions have been filled. Group 1: Board of Directors Election - The third board of directors was elected during the annual general meeting on June 11, 2025, with Zhao Yan, Guo Jiajun, Li Yizheng, Wang Hui, Yu Jing, and Chen Yuxin as non-independent directors, and Yao Yang, Chen Daliang, and Xu Wenming as independent directors [1][2] - Zhao Yan was elected as the chairman of the third board of directors, with a term starting from the approval date until the end of the board's term [2] - The board established several specialized committees, including the Strategy Committee, Audit Committee, Nomination Committee, Compensation and Assessment Committee, ESG Committee, and Risk Management Committee, with independent directors holding a majority in key committees [2][3] Group 2: Senior Management Appointments - Zhao Yan was appointed as the General Manager, with Guo Jiajun, Li Yizheng, Wang Hui, and Xiang Maogong appointed as Deputy General Managers. Li Yizheng also serves as the Board Secretary, and Wang Hui as the Chief Financial Officer [4] - The appointments of senior management personnel were approved by the Nomination Committee, and their qualifications were reviewed accordingly [4] - Li Yizheng holds the qualification certificate for the Board Secretary of the Shanghai Stock Exchange's Sci-Tech Innovation Board, confirming his eligibility for the position [4] Group 3: Management Profiles - Zhao Yan, born in July 1966, holds a bachelor's degree in biology and an MBA from Fordham University. She has held various leadership roles within the company since 2000 [5] - Guo Jiajun, born in September 1975, has an MBA from Fordham University and has served in various managerial positions within the company since 2002 [6] - Li Yizheng, born in September 1984, holds a master's degree in investment studies and has extensive experience in investment banking prior to joining the company in 2021 [7] - Wang Hui, born in September 1983, is a CPA and has held various financial management roles before joining the company in September 2023 [8] - Xiang Maogong, born in February 1984, has a background in microbiology and has worked in various roles in the pharmaceutical industry [8]

证券代码：688363 证券简称：华熙生物 公告编号：2025-022 华熙生物科技股份有限公司 关于公司董事会完成换届选举 暨聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 11 日召开 公司 2024 年年度股东大会，选举产生了公司第三届董事会成员。同日，公司召 开了第三届董事会第一次会议，选举产生了第三届董事会董事长、第三届董事会 各专门委员会委员及召集人，并聘任高级管理人员。具体情况公告如下： 一、 董事会换届选举情况 （一）第三届董事会成员 经公司 2024 年年度股东大会选举，赵燕女士、郭珈均先生、李亦争先生、 汪卉先生、于静女士、陈玉鑫先生当选为公司第三届董事会非独立董事，姚洋先 生、陈达亮先生、徐文鸣先生当选为公司第三届董事会独立董事。第三届董事会 任期为自公司股东大会审议通过之日起三年。上述董事个人简历详见公司于 2025 年 5 月 20 日在上海证券交易所披露的《华熙生物科技股份有限公司关于董 事会换届选举的公告 ...